June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017

Intravitreal RTPA injection for macular hemorrhage: long term follow up.
Author Affiliations & Notes
  • Isabella D'Agostino
    Biomedical and Clinacal Science "Luigi Sacco", Sacco Hospital Eye clinic, Milan, Italy
  • Sara Bochicchio
    Biomedical and Clinacal Science "Luigi Sacco", Sacco Hospital Eye clinic, Milan, Italy
  • Matteo Giuseppe Cereda
    Biomedical and Clinacal Science "Luigi Sacco", Sacco Hospital Eye clinic, Milan, Italy
  • Giovanni Staurenghi
    Biomedical and Clinacal Science "Luigi Sacco", Sacco Hospital Eye clinic, Milan, Italy
  • Footnotes
    Commercial Relationships   Isabella D'Agostino, None; Sara Bochicchio, None; Matteo Cereda, Bayer (C); Giovanni Staurenghi, Alcon (C), Alcon (R), Allergan (C), Bayer (C), Bayer (R), Boehringer Ingelheim (C), Genentech (C), Heidelberg Engineering (C), Heidelberg Engineering (R), Novartis (F), Novartis (C), Novartis (R), Ocular Instruments (P), Optos (C), Optuvue (F), Roche (C), Zeiss (F), Zeiss (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1934. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Isabella D'Agostino, Sara Bochicchio, Matteo Giuseppe Cereda, Giovanni Staurenghi;
      Intravitreal RTPA injection for macular hemorrhage: long term follow up.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1934.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate long term visual outcome and progression of exudative age related macular degeneration (wet-AMD) in terms of choroidal neovascularization (CNV) activity and OCT B-Scan changes in patients treated with intravitreal injection of recombinant tissue plasminogen activator (rTPA) for recent onset of submacular hemorrhage.

Methods : This is a retrospective case series of 25 patients diagnosed with submacular hemorrhage associated with CNV and treated by intravitreal rTPA (50 mg in 0.1 ml) and gas (0.3 cc SF6 99%).The procedure was performed within 14 days from bleeding in all the patients. An anti-VEGF drug was injected in each eye at the day of diagnosis and preceded the pneumatic displacement from 1 to 5 days. Each eye was scanned with SD-OCT(HRA Spectralis, Heidelberg Engineering) at baseline, one day, one week and one month after the main procedure; a pro re nata (PRN) approach was used thereafter. We evaluated visual acuity (VA) before and after procedure, CNV reactivation based on number of anti-VEGF intravitreal injections necessary in the following years.

Results : At baseline the mean VA was 1.3/10 (SD ±0.11) and rise to 2.1/10 (SD ±0.19) at first evaluation after the injection. Ten patients didn't require further treatments because of CNV contraction and poor residual VA (mean 0.03,SD ±0.02), a complete blood dislocation was obtained just in 3 of them. Eleven patients showed a VA improvement from 1.7/10 (DV ±0.10) to 3.5/10 (DV ±0.16) associated with a complete (7/11) o partial (4/11) dislocation of the hemorrhage from macula within 7 days. In eight of them further anti-VEGF intravitreal injections were necessary during the follow up (mean number of injections was 5.5 in the first year,2.7 per year during follow up), while in 3 patients CNV didn’t show other signs of activity. We lost 4 patients at follow up visits. Mean follow up time was 19,8 months (max 39,min 4). In one case vitreous hemorrhage complicated the main procedure.

Conclusions : In our series, best VA outcome correlated with a complete dislocation of the submacular hemorrhage within 7 days. When procedure failed a fibrotic contraction of the CNV occurred and VA outcome was poor. After a complete dislocation of the blood CNV can reactivate. Rate of reactivation is higher during the first year and tends to reduce thereafter.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×